GeneDx Holdings Corp. (WGSWW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GeneDx Holdings Corp. (WGSWW) trades at $0.00 with AI Score 56/100 (Grade B). GeneDx Holdings Corp. provides genomics-related diagnostic and information services, operating in the healthcare sector. Market cap: $1.61B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for WGSWW: WGSWW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates WGSWW against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
WGSWW: the 7 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →GeneDx Holdings Corp. (WGSWW) Healthcare & Pipeline Overview
GeneDx Holdings Corp. offers genomics-related diagnostic services, leveraging its Centrellis AI platform to provide comprehensive health insights. Focusing on pediatrics, rare diseases, and hereditary cancer screening, the company operates within the competitive healthcare information services sector, facing challenges and opportunities in a rapidly evolving market.
What Is the Investment Thesis for WGSWW?
GeneDx Holdings Corp. presents a compelling investment case within the healthcare information services sector, driven by its Centrellis AI platform and focus on specialized genetic testing. The company's gross margin of 68.5% indicates strong pricing power and efficient operations. However, the negative profit margin of -4.9% and a high P/E ratio of -96.58 warrant careful consideration. Future growth will likely depend on expanding the adoption of Centrellis and penetrating key markets in pediatrics, rare diseases, and hereditary cancer screening. The company's high beta of 2.15 suggests significant volatility relative to the market. Investors should monitor the company's ability to achieve profitability and manage its operational costs effectively. The pending AI analysis could provide further insights into the company's technological capabilities and market potential.
Based on FMP financials and quantitative analysis
WGSWW Key Highlights
- Gross Margin of 68.5% indicates strong pricing power in its diagnostic services.
- Focus on pediatrics, rare diseases, and hereditary cancer screening positions the company in high-demand areas of genetic testing.
- Centrellis AI platform provides a technological advantage in integrating and synthesizing clinical and genomic data.
- Negative Profit Margin of -4.9% highlights the need for improved operational efficiency.
- High Beta of 2.15 suggests significant volatility compared to the broader market.
Who Are WGSWW's Competitors?
WGSWW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EUDA EUDA Health Holdings Limited operates a digital health platform, offering virtual consultations for non-emergency medical | $13.96 | +0.58% | $26.07M | 46 |
| MLEC Moolec Science S.A. | $7.95 | -0.19% | $5.77M | 55 |
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| KURIU Alkuri Global Acquisition Corp. | $9.50 | -5.19% | 56 | |
| DLHTF Dialogue Health Technologies Inc. | $3.79 | +0.59% | $254.80M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WGSWW's Key Strengths?
- Proprietary Centrellis AI platform for advanced data analysis.
- Focus on high-growth areas like pediatrics and rare diseases.
- Strong gross margin indicates efficient operations.
- Expertise in genomics and genetic testing.
What Are WGSWW's Weaknesses?
- Negative profit margin indicates operational inefficiencies.
- High beta suggests significant market volatility.
- Reliance on specific diagnostic areas may limit growth potential.
- Limited geographic reach compared to larger competitors.
What Could Drive WGSWW Stock Higher?
- Expansion of Centrellis AI platform capabilities to include new diagnostic applications.
- Strategic partnerships with hospitals and research institutions to broaden data access and collaboration.
- Geographic expansion into emerging markets to increase customer base and revenue streams.
What Are the Key Risks for WGSWW?
- Financial-distress signal — its Altman Z-Score of -3.10 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-27.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players in the healthcare information services industry.
- Rapid technological advancements may render existing solutions obsolete.
- Regulatory changes and reimbursement policies may impact revenue streams.
- Data privacy and security concerns may limit data access and collaboration.
What Are the Growth Opportunities for WGSWW?
- Expansion of Centrellis Platform: GeneDx can expand the capabilities of its Centrellis AI platform to include additional diagnostic applications and predictive analytics. The global AI in healthcare market is projected to reach $95 billion by 2030, offering a significant opportunity for growth. Timeline: Ongoing.
- Strategic Partnerships: Forming partnerships with hospitals, research institutions, and pharmaceutical companies can broaden GeneDx's reach and access to patient data. Collaborations can drive the development of new diagnostic tests and screening solutions. Timeline: Ongoing.
- Geographic Expansion: Expanding operations into new geographic markets, particularly in Europe and Asia, can increase GeneDx's customer base and revenue streams. The global genetic testing market is expected to reach $25 billion by 2028, with significant growth potential in emerging markets. Timeline: 2-3 years.
- Development of New Genetic Tests: Investing in the development of new genetic tests and screening solutions can address unmet needs in specific disease areas. Focus on rare diseases and personalized medicine can drive innovation and market differentiation. Timeline: 1-2 years.
- Increased Focus on Data Analytics: Leveraging the data generated by its diagnostic services to provide insights and analytics to healthcare providers and researchers. The market for healthcare analytics is expected to reach $75 billion by 2027, offering a substantial growth opportunity. Timeline: Ongoing.
What Opportunities Does WGSWW Have?
- Expansion of Centrellis platform to new diagnostic applications.
- Strategic partnerships with hospitals and research institutions.
- Geographic expansion into emerging markets.
- Development of new genetic tests and screening solutions.
What Threats Does WGSWW Face?
- Intense competition from established players in the healthcare information services industry.
- Rapid technological advancements may render existing solutions obsolete.
- Regulatory changes and reimbursement policies may impact revenue streams.
- Data privacy and security concerns may limit data access and collaboration.
What Are WGSWW's Competitive Advantages?
- Proprietary Centrellis AI platform provides a competitive advantage in data analysis and health insights.
- Focus on specialized areas like pediatrics and rare diseases creates a niche market position.
- Strong relationships with hospitals and research institutions enhance data access and collaboration.
- Expertise in genomics and genetic testing provides a barrier to entry for new competitors.
What Does WGSWW Do?
GeneDx Holdings Corp., established in 2017 and headquartered in Stamford, Connecticut, operates as a provider of genomics-related diagnostic and information services. Through its subsidiaries, the company offers a range of genetic diagnostic tests, screening solutions, and information services. These services primarily focus on pediatrics, rare diseases affecting both children and adults, and hereditary cancer screening. At the core of GeneDx's offerings is Centrellis, an AI-driven health intelligence platform. Centrellis integrates digital tools and artificial intelligence, enabling scientists to ingest and synthesize clinical and genomic data. This integration facilitates the delivery of comprehensive health insights to healthcare professionals and patients. GeneDx aims to improve diagnostic accuracy and treatment strategies through advanced genomic analysis. The company's focus on AI-driven solutions and specialized diagnostic areas positions it within the evolving landscape of personalized medicine and healthcare information.
What Products and Services Does WGSWW Offer?
- Provides genetic diagnostic tests for various conditions.
- Offers screening solutions for pediatrics, rare diseases, and hereditary cancer.
- Develops and utilizes the Centrellis AI-driven health intelligence platform.
- Integrates digital tools and artificial intelligence for data analysis.
- Synthesizes clinical and genomic data to deliver health insights.
- Focuses on improving diagnostic accuracy and treatment strategies.
How Does WGSWW Make Money?
- Generates revenue through the sale of genetic diagnostic tests and screening services.
- Offers its Centrellis AI platform as a service to healthcare providers.
- Forms partnerships with hospitals and research institutions for data access and collaboration.
What Industry Does WGSWW Operate In?
GeneDx Holdings Corp. operates within the medical and healthcare information services industry, a sector experiencing rapid growth due to advancements in genomics and personalized medicine. The market is characterized by increasing demand for genetic testing and AI-driven diagnostic tools. Companies like BJDX, EUDA, GLMD, ISPC, and MLEC represent the competitive landscape. GeneDx's focus on specific areas like pediatrics and rare diseases allows it to carve out a niche in this competitive environment. The industry is driven by technological innovation and the need for more accurate and efficient diagnostic solutions.
Who Are WGSWW's Key Customers?
- Pediatricians and pediatric specialists.
- Oncologists and cancer centers.
- Individuals seeking genetic screening for hereditary conditions.
- Hospitals and healthcare systems.
- Research institutions and pharmaceutical companies.
ROE -28%Key Financial Metrics
Return on equity for GeneDx Holdings Corp. stands at -27.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.9%, the inverse of the P/E and a quick read on earnings relative to price.
GeneDx Holdings Corp. (WGSWW) Valuation Context
Valued at $1.61B, WGSWW is classified as a small-cap stock. Relative to its peer group, WGSWW's quantitative score of 56/100 is roughly in line with the peer average of 61/100.
Company Profile
GeneDx Holdings Corp. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Stamford, US. The company is led by CEO Katherine A. Stueland. WGSWW has traded publicly since 2021.
F-Score 3/9Financial Health
GeneDx Holdings Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.10 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project GeneDx Holdings Corp. revenue of about $478.4M for fiscal 2026, with EPS near $-0.07. The estimate reflects 10 contributing analysts.
WGSWW Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary Centrellis AI platform for advanced data analysis.
- Focus on high-growth areas like pediatrics and rare diseases.
- Strong gross margin indicates efficient operations.
- Expertise in genomics and genetic testing.
Bear Case
- Negative profit margin indicates operational inefficiencies.
- High beta suggests significant market volatility.
- Reliance on specific diagnostic areas may limit growth potential.
- Limited geographic reach compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
WGSWW Latest News
No recent news available for WGSWW.
WGSWW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for WGSWW.
Price Targets
Wall Street price target analysis for WGSWW.
WGSWW MoonshotScore
What does this score mean?
The MoonshotScore rates WGSWW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Katherine A. Stueland
CEO
Katherine A. Stueland is the CEO of GeneDx Holdings Corp. Her background includes extensive experience in the healthcare and diagnostics industries. Prior to joining GeneDx, she held leadership positions at various healthcare companies, focusing on strategic growth, operational efficiency, and market expansion. Her expertise spans across areas such as genomics, personalized medicine, and healthcare information technology. She is responsible for overseeing the company's overall strategy, operations, and financial performance.
Track Record: Since becoming CEO, Katherine A. Stueland has focused on expanding the capabilities of the Centrellis AI platform and driving growth in key diagnostic areas. She has overseen strategic partnerships and initiatives aimed at increasing market share and improving operational efficiency. Her leadership has been instrumental in navigating the competitive landscape of the healthcare information services industry.
What Investors Ask About GeneDx Holdings Corp. (WGSWW) — Healthcare
What does GeneDx Holdings Corp. do?
GeneDx Holdings Corp. provides genomics-related diagnostic and information services, focusing on pediatrics, rare diseases, and hereditary cancer screening. The company's core offering is the Centrellis AI platform, which integrates digital tools and artificial intelligence to synthesize clinical and genomic data. This platform enables the delivery of comprehensive health insights to healthcare professionals and patients, improving diagnostic accuracy and treatment strategies. GeneDx generates revenue through the sale of genetic diagnostic tests, screening services, and access to its Centrellis platform.
What do analysts say about WGSWW stock?
Currently, there is no available AI analysis for WGSWW. Investors should conduct their own due diligence and consider factors such as the company's financial performance, market position, and growth potential. Key valuation metrics include the negative P/E ratio of -96.58 and the gross margin of 68.5%. Growth considerations include the expansion of the Centrellis platform, strategic partnerships, and geographic expansion. The high beta of 2.15 suggests significant volatility relative to the market. Further analysis is needed to assess the long-term investment potential of WGSWW.
What are the main risks for WGSWW?
GeneDx Holdings Corp. faces several risks, including intense competition from established players in the healthcare information services industry. Rapid technological advancements may render existing solutions obsolete, requiring continuous innovation and investment. Regulatory changes and reimbursement policies may impact revenue streams. Data privacy and security concerns may limit data access and collaboration. Additionally, the company's negative profit margin indicates operational inefficiencies that need to be addressed to achieve sustainable profitability.
What are the key factors to evaluate for WGSWW?
GeneDx Holdings Corp. (WGSWW) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does WGSWW data refresh on this page?
WGSWW prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven WGSWW's recent stock price performance?
GeneDx Holdings Corp. (WGSWW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Centrellis AI platform for advanced data analysis. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider WGSWW overvalued or undervalued right now?
Valuing GeneDx Holdings Corp. (WGSWW) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying WGSWW?
Before investing in GeneDx Holdings Corp. (WGSWW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for WGSWW, limiting comprehensive insights.
- Financial data based on available information as of 2026-03-17.